The now chronic nature of HIV has been a major advancement in AIDS care, but as with any chronic condition brings with it the recognition of other sequelae, including the HIV-associated neurocognitive disorder (HAND). In addition, as a natural consequence of the chronicity of infection and reduced new infection, the face of HIV infection is changing to an older population;soon over half of infected individuals will be 50 years of age or greater. As detailed in our Research Plan, we will now take the lessons others and we have learned about HIV and the brain and apply it to the changing epidemic - the graying of HIV, the nature of the effects on the brain of the chronic infection, means to treat HIV in the brain, and potential interaction with conditions linked to aging and other neurodegenerative disorders. We will set about this through the Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center as described in this proposal. We will accomplish four Action Items novel Biomarkers, the Role of Macrophages CNS Penetrating Antiviral Therapeutics, and the Effects on Chronic CNS Infection on Neurons, and support our investigators'research efforts through our Cores (Administrative, Biophysical Assessment Cells/Tissues/Animals, Developmental, International, Phenomics, Systems Biology, and Therapeutics). Our goals driven by our framework: researching of the chronicity of HIV infection in the CNS with a systems biology approach.
While HIV infected individuals are living longer, damaging effects of HIV persists on the brain, and as infected individuals age, may interact with other neurodegenerative disorders. Here we will investigate this change in the epidemic, and research new ways to diagnose, predict, treat, and prevent brain damage induced by HIV.
|Hu, Guoku; Liao, Ke; Yang, Lu et al. (2017) Tat-Mediated Induction of miRs-34a & -138 Promotes Astrocytic Activation via Downregulation of SIRT1: Implications for Aging in HAND. J Neuroimmune Pharmacol 12:420-432|
|Stauch, Kelly L; Emanuel, Katy; Lamberty, Benjamin G et al. (2017) Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals. J Neurovirol 23:795-807|
|Li, Weizhe; Gorantla, Santhi; Gendelman, Howard E et al. (2017) Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains. Dis Model Mech 10:1489-1502|
|Kevadiya, Bhavesh D; Bade, Aditya N; Woldstad, Christopher et al. (2017) Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. Acta Biomater 49:507-520|
|Araínga, Mariluz; Edagwa, Benson; Mosley, R Lee et al. (2017) A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology 14:17|
|Sandkovsky, Uriel; Podany, Anthony T; Fletcher, Courtney V et al. (2017) Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. J Antimicrob Chemother 72:200-204|
|Gnanadhas, Divya Prakash; Dash, Prasanta K; Sillman, Brady et al. (2017) Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. J Clin Invest 127:857-873|
|Shahnaz, Gul; Edagwa, Benson J; McMillan, JoEllyn et al. (2017) Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. Nanomedicine (Lond) 12:99-115|
|Edagwa, Benson; McMillan, JoEllyn; Sillman, Brady et al. (2017) Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv 14:1281-1291|
|Guo, Dongwei; Zhou, Tian; Araínga, Mariluz et al. (2017) Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. J Acquir Immune Defic Syndr 74:e75-e83|
Showing the most recent 10 out of 346 publications